Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003-2008

Diabetic Medicine

Volumn 29, Issue 2, 2012, Pages 198-206

  Fharm E ^a   Cederholm, J ^b   Eliasson, B ^c   Gudbjornsdottir S ^c   Rolandsson, O ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood pressure; Diabetes mellitus; Dyslipidaemia; HbA 1c; Myocardial infarction

Indexed keywords

ANTILIPEMIC AGENT; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE; TREND STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 84855776296     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03425.x     Document Type: Article

References (34)

1. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998; 21: 539-545.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2581.
3. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran S, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
5. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-2110.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
8. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
9. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
11. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B. The National Diabetes Register in Sweden. An implementation of the St Vincent declaration for quality improvement in diabetes care. Diabetes Care 2003; 26: 1270-1276.
12. Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes register (NDR). Diabet Med 2009; 26: 53-60.
13. Hoelzel W, Weykamp C, Jeppsson J-O, Miedema K, Barr JR, Goodall I et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
14. Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson J-O, Little R et al., on behalf of the IFCC Working Group on Standardization of HbA1c Statistical methods for monitoring the relationship between the IFCC measurement reference procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan and Sweden. Clin Chem 2008; 54: 1379-1385.
15. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdottir S. The gap between guidelines and reality: Type 2 diabetes in a national register 1996-2003. Diabet Med 2005; 22: 1420-1426.
16. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
17. Medical Products Agency. Prevention of atherosclerotic cardiovascular disease. 2006 (Swedish, online treatment recommendations). Available at .lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/080313-primarprevention.pdf Last accessed 16 April 2011.
18. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in TypeII diabetes (UKPDS56). Clin Science 2001; 101: 671-679.
19. Benner JS, Erhardt L, Flammer M, Moller RA, Rajicic N, Changela K et al. A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile. Int J Clin Pract 2008; 62: 1484-1498.
20. Fhärm E, Rolandsson O, Johansson EE. 'Aiming for the stars'- GPs' dilemmas in the prevention of cardiovascular disease in type 2 diabetes patients: focus group interviews. Fam Pract 2009; 26: 109-114.
21. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study. a randomized controlled study. Arch Intern Med 2007; 167: 2296-2303.
22. Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover S. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Prev Med 1998; 27: 730-737.
23. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. Br Med J 2000; 320: 686-690.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
25. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 703-713.
26. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26: 142-148.
27. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30: 1292-1294.
28. Madhok V, Fahey T. Cardiovascular risk estimation: important but may be inaccurate. Br Med J 2006; 332: 1422.
29. Simmons RK, Khaw TT, Coleman RL, Wareham NJ, Price HC, Griffin SJ et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009; 32: 708-713.
30. Kengne AP, Patel A, Colagiuri S, Heller S, Hamet P, Marre M et al. Predictive accuracy of the Framingham and UKPDS risk equations in estimating the probability of cardiovascular events in a multi-national contemporary population with diabetes. International Diabetes Federation, oral presentation 0198. 20th World Diabetes Congress, Montreal, Canada, 18-22 October 2009.
31. Liu J, Hong Y, D'Agostino R, Wu Z, Wang W, Sun J et al. Predictive value for the Chinese population of the Framingham risk assessment tool compared with the Chinese multi-provincial cohort study. J Am Med Assoc 2004; 291: 2591-2599.
32. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjörnsdottir S et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13087 patients. Diabetologia 2009; 52: 65-73.
33. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009; 32: 429-431.
34. Hivert M-F, Grant RW, Shrader P, Meigs JB. Identifying primary care patients at risk for future diabetes and cardiovascular disease using electronic health records. BMC Health Ser Res; 29: 170.